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Abstract
Background: The oncoprotein HER-2 is over-expressed and/or has undergone gene amplification in
between 20 to 30% of breast and ovarian cancers. HER-2 amplified breast cancer is associated with a poor
prognosis and increased resistance to chemo- and hormonal therapy. Data supporting the transforming
potential of HER-2 are irrefutable but the mechanism by which HER-2 contributes to this process is
complex and a unified model of HER2-induced increased cell proliferation and survival has not emerged.
To understand the initial event(s) that take place by HER-2 over expression, we studied the effect of short
term induction of HER-2 expression in the MCF7 breast cancer cell line.
Methods:  We examined the modulation of apoptotic pathways by tetracycline-regulated HER-2
expression for 48 hrs in the MCF7 breast cancer cell line. Specific inhibitors were used to determine
signalling pathways that are required for HER-2 induced up-regulation of survivin.
Results: Tetracycline regulated short term over expression of HER-2 in the MCF7 cell line increased the
antiapoptotic proteins Bcl-2 and survivin levels. Significant increase of extracellular signal-related kinase
(ERK) activation but not AKT1, AKT2 and STAT3 was observed in HER-2 over-expressing MCF7 cells.
Specific inhibitors of ERK, and phosphoinositide-3 kinase (PI3K), inhibited the HER-2 induced up-
regulation of survivin. We did not observe a change in survivin and NF-κB promoter activity in HER-2
expressing MCF7 cells.
Conclusion: Our results indicate that short term over expression of HER-2 up regulates antiapoptotic
proteins Bcl-2 and survivin in MCF7 cells. We determined that survivin is up-regulated via ERK activation
and PI3K signalling. Additionally we show that survivin up-regulation is not at transcriptional level. These
data provide insight into the mechanism(s) by which induction of HER-2 over expression up-regulates
survivin and Bcl-2 and identifies new targets for therapy of breast cancer.
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Background
Impaired apoptosis is critical in cancer development and
is a major barrier to effective treatment. Apoptosis is exe-
cuted by intracellular cysteine proteases called caspases.
Two pathways lead to the caspase activation – the extrinsic
and intrinsic pathways. The extrinsic pathway is initiated
by ligation of death receptors [1]. The intrinsic pathway
requires disruption of mitochondrial membranes and
release of cytochrome C [2]. Molecules and signalling
events that regulate apoptosis affect disease progression
and the efficacy of chemotherapy because most chemo-
therapy kills cancer cells by inducing apoptosis [3].
HER-2 is a key molecule in the regulation of apoptosis in
breast cancer cells [4]. Approximately 25–30 percent of
breast cancers have amplification of the HER-2/neu gene
or over express HER-2, which correlates with poor prog-
nosis and resistance to therapy [5]. The ERBB/HER family
of proteins consists of four tyrosine kinase, membrane
bound receptors (HER1-4) and more than 13 polypeptide
extracellular ligands. HER-2 lacks the capacity to interact
with ligand [6], whereas the kinase activity of HER3 is
defective [7]. Despite this lack of autonomous ability to
respond to a ligand, both HER-2 and HER3 form het-
rodimeric complexes with other HER receptors that are
capable of generating potent cellular signals. HER-2 con-
taining heterodimers have a higher affinity and a broader
specificity for various ligands than the other dimer recep-
tor complexes, owing to slower rates of ligand dissocia-
tion. Also, HER-2-containing heterodimers have a slower
rate of endocytosis and a higher rate of recycling back to
the cell surface. These features translate to potent
mitogenic and anti-apoptotic signals [8,9]. HER-2 signal-
ling is mediated by several sequentially activated protein
kinases, some of which (ERK, JNK, p38MAPK) belong to
super family of mitogen activated protein kinases (MAPK)
[10,11]. Other components of the intracellular signalling
cascade activated by the ERBB/HER family of receptors
include PI3K dependent activation of AKT [12], apoptotic
signaling through Bcl-2 [13] and the inhibitor of apopto-
sis (IAP) families of proteins [14].
The Bcl-2 family plays a pivotal role in the regulation of
the mitochondrial "intrinsic" pathway of apoptosis [15].
The Bcl-2 family is subdivided into antiapoptotic mem-
bers, including Bcl-2 and Bcl-XL, and proapoptotic mem-
bers, including Bax and Bak [16,17]. Overexpression of
antiapoptotic molecules Bcl-2 and Bcl-XL blocks cyto-
chrome C release in response to apoptotic stimuli.
Expression of survivin, an inhibitor-of-apoptosis protein
(IAP) family members, is also associated with resistance
to apoptosis [18]. Survivin inhibits activation of caspase-
9, which is required for the initiation of the intrinsic mito-
chondrial pathway of apoptosis [19].
In this study we examined the modulation of apoptotic
pathways by tetracycline-regulated HER-2 expression in
the MCF7 breast cancer cell line. Our results indicate that
HER-2 up regulates antiapoptotic proteins Bcl-2 and sur-
vivin as reported previously [20,21]. Using specific signal-
ling inhibitors we determined that survivin is up-
regulated via ERK activation and PI3K signalling. Addi-
tionally we show that survivin upregulation is not at tran-
scriptional level. These data provide insight into the
mechanism(s) by which HER-2 over expression protects
breast cancer cells from apoptosis and identifies new tar-
gets for therapy of breast cancer.
Methods
Cell Culture
The human breast cancer cell line MCF-7 was obtained
from the American Type Culture Collection (ATCC, Rock-
ville, MD) and maintained in Dulbecco's Modified Eagle's
Medium (Invitrogen, Grand Island, NY) supplemented
with 10% feotal bovine serum (FBS) (Invitrogen). Cell
lines were incubated under standard conditions in a 37°C
humidified 5% CO2 atmosphere.
Reagents and Antibodies
FuGENE 6 transfection reagent was obtained from Roche
Applied Science (Indianapolis, IN), pTet-On and ptTS
plasmids from Clontech (Palo Alto, CA), dual-luciferase
reporter assay system from Promega (Madison, CA), ECL™
western blotting detection reagents from Amersham Bio-
sciences (Little Chalfont, Buckinghamshire, UK), BSA pro-
tein assay kit from Pierce (Rockford, IL), and U0126,
LY294002, AKT inhibitor IV and PD98059 were pur-
chased from Calbiochem (La Jolla, CA).
Donkey anti-rabbit and anti-mouse IgG peroxidase-
labeled antibodies and Cy3-conjugated donkey anti-rab-
bit IgG were obtained from Amersham Biosciences (Pis-
cataway, NJ), rabbit anti-survivin from Novus Biologicals
(Littleton, CO), mouse anti-Bcl-2 from (BD Biosciences),
rabbit anti-ERB2 from (Delta Bio labs), rabbit ant-pERB2
was from Upstate (Charlottesville, VA), rabbit anti-Akt
and rabbit anti-phospho Ribosomal protein S6 (S235)
from Cell Signaling Technology (Danvers, MA), rabbit
anti-phoso-Akt S473 from (R&D), and rabbit anti-stat3 C-
2 was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA).
Inducible expression of HER-2 in the MCF-7 cell line
To produce HER-2 expressing, tetracycline inducible
MCF-7 cells, two rounds of stable transfection and selec-
tion were used. In the first round, MCF-7 cells were co-
transfected with a pTet-On and ptTS at a ratio of 1:10.
pTet-ON carries a tetracycline-inducible transcriptional
transactivator and ptTS encodes a transcriptional silencer,
which binds to the tetracycline response element (TRE) inBMC Cancer 2008, 8:129 http://www.biomedcentral.com/1471-2407/8/129
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the absence of tetracycline and decreases background pro-
moter activity. After G418 selection, clones were tested for
basal and inducible promoter activity with the tetracycline
inducible luciferase reporter plasmid, pTRE-luc (Clon-
tech). The clone that demonstrated the highest ratio of
induced/basal activity was then transfected with pTRE-
HER2, a construct in which the ErbB2 cDNA was cloned
under control of TRE in a pTRE-hygro backbone. After a
second round of selection with Hygromycin B, clones
were isolated and screened for background and doxycy-
cline-inducible (2 µg/ml) expression of HER-2 by western
blotting (described below).
Western blotting
Cells were lysed in buffer (20 mM Tris-HCl pH 8, 100 mM
NaCl, 1 mM EDTA, 1% NP-40). Protein concentrations
were determined using the BSA protein assay kit. Twenty-
five µgs of whole-cell protein lysate from each sample was
diluted in 25 µl of SDS loading buffer (4% SDS, 2% glyc-
erol, 0.01% bromphenol blue, 4% β-mercaptoethanol
and 125 mM Tris-HCl, pH 6.8), incubated for 5 min at
98°C and 5 min on ice and then centrifuged at 6000 rpm
in a microcentrifuge at room temperature. Proteins in the
supernatant were resolved on 10% SDS/polyacrylamide
gels and transferred to PVDF membranes. Membranes
were blocked for 1 h in 5% nonfat dry milk in TBST (10
mM Tris-HCl pH 7.5, 150 mM NaCl and 0.1% Tween 20)
and probed for 2 h with primary antibodies diluted in
TBST/5% nonfat dry milk as per the supplier's recommen-
dations. Membranes were then washed with TBST 20 min-
utes × 3 and incubated for 1 h with horseradish
peroxidase-labeled secondary antibodies in TBST. After an
additional four washes with TBST, bound antibody was
visualized by chemiluminescence.
Cloning of survivin promoter in pGL3-Basic vector to 
produce Survivin-Luciferase
Survivin promoter (nucleotides 1821 – 2800, accession




[22]. The PCR product was first cloned into T-Vec-
tor™(Promega) and subsequently sub-cloned into the
pGL3-Basic vector to produce Survivin-Luc. Fidelity of
PCR cloning was verified by sequencing survivin pro-
moter. MCF-HER2 cells, untreated or induced with doxy-
cycline for 48 hours, were transiently transfected with
Survivin-Luc plasmid
Results
Tetracycline-inducible overexpression of HER-2 in MCF7 
cell line
The HER-2 cDNA was cloned under the control of tetracy-
cline response element in pTREhygro as described above,
to produce the plasmid pTRE-HER2. The MCF7 cell line
was transfected with pTRE-HER2, and clones were iso-
lated by selection with hygromycin B and screened for tet-
racycline inducible expression of HER-2. Doxycyclin-
inducible expression of HER-2 was quantified by Western
blotting. Three HER-2-transfected clones (H1, H2 and
H3) and two vector-transfected control clones (C1 and
C2) were incubated with or without doxycycline. Whole
cell protein extracts were prepared and evaluated for
ErbB2 expression by western blotting (Figure 1). Induc-
tion of HER-2 was quantified by NIH Java image process-
ing program ImageJ. In the presence of Dox HER-2 was
increased 4.1, 2.7 and 2.8 fold compared to without Dox
in H1, H2 and H3 clones respectively. No significant dif-
ference in HER-2 with or without Dox was found in the
vector control clones (C1 and C2).
Activated HER-2 up-regulates survivin expression in MCF-
7 cells
Due to a significant overlap of biological features attribut-
able to the overexpression of HER-2 and survivin (i.e.,
enhanced proliferation, improved cell survival, resistance
to chemotherapy, correlation with poor prognosis, etc)
and the report of survivin regulation by HER-2 [21], we
investigated survivin regulation in HER-2-overexpressing
MCF7 cells. Two control clones (C1 and C2) and three
pTRE-HER2 clones (H1, H2 and H3) were grown in the
presence or absence of doxycycline for 48 hours. Whole
cell protein extracts were prepared and analyzed for
expression of survivin and an active, phosphorylated form
of HER-2 (phospho-ErbB2). The experiments were
repeated twice with separately collected protein extracts.
Figure 2 demonstrates pronounced up-regulation of sur-
vivin protein in doxycycline-treated cells, which parallels
the levels of phospho-HER-2.
Up regulation of survivin is not due to an increase in G2/M 
cells in HER 2-overexpressing population
Survivin is preferentially expressed during the G2 and M
phases of the cell cycle. We therefore performed a cell
cycle analysis to rule out the possibility that up-regulation
of survivin is due to merely an increase of a fraction of G2/
M cells in the HER-2-overexpressing population. Cells
were cultured with (Dox +) or without (Dox -) doxycy-
cline for 48 hours, incubated with propidium iodide and
analyzed for cell cycle distribution by flow cytometry. As
shown in table 1, no increase in the G2/M cell fraction was
found in doxycycline-treated MCF-HER2 cultures.BMC Cancer 2008, 8:129 http://www.biomedcentral.com/1471-2407/8/129
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Activity of the survivin promoter is not enhanced by HER-
2 overexpression in MCF7- cells
Survivin expression is regulated both at the levels of tran-
scription [22] and protein stability [23]. Understanding
the precise level at which ErbB2 up-regulates survivin
expression will help to delineate the underlying signal
transduction pathways and will allow better targeting of
survivin in ErbB2-overexpressing breast cancer cells. We
cloned a 976 bp genomic DNA fragment containing the
survivin promoter in the reporter plasmid pGL3. MCF7-
HER2 cells were plated in duplicate wells at a concentra-
tion of 5 × 104 cells per well in 24 well plates. Doxycycline
(dox) or saline control was added 16 hours later and incu-
bation continued for additional 24 hours, after which
cells received fresh serum-containing medium with or
without Dox. Cells were then co-transfected with Sur-
vivin-Luc plasmid and pRL-TK, which contains Renilla
luciferase sequence under control of TK promoter. 48
hours later cells were harvested and dual-luciferase assay
was performed per manufacturer's instructions. Data are
presented as a ratio of Firefly/Renilla luciferase activity ×
100 in Figure 3. The activity of survivin promoter was not
increased in doxycycline-treated, HER-2-overexpressing
cells as compared to cells with background level of HER-2
expression grown in the absence of doxycycline.
Bcl-2 is up-regulated in HER-2 expressing MCF7 cell line
Over expression of Bcl-2 blocks cytochorme C release in
response to apoptotic stimuli making cells resistant to
many chemotherapeutic agents. We determined the Bcl-2
status in MCF7-HER2 cells. MCF7-HER2 clones were
grown in the presence or absence of doxycycline for 48
hours. Whole cell protein extracts were collected and ana-
lyzed for expression of Bcl-2 by western blot (Figure 4).
Bcl-2 protein is significantly up-regulated in doxycycline-
treated MCF7-HER2 cells in which HER-2 expression is
induced.
Doxycycline-inducible expression of HER-2 protein Figure 1
Doxycycline-inducible expression of HER-2 protein. 
Three pTRE-HER2-transfected clones (H1, H2 and H3) and 
two pTRE-transfected control MCF-7 clones (C1 and C2) 
were incubated with or without doxycycline. Whole cell pro-
tein extracts were collected and evaluated for HER2 expres-
sion by western blotting using HER2 antibodies.
Activated HER-2 up-regulates survivin expression Figure 2
Activated HER-2 up-regulates survivin expression. Three pTRE-HER2-transfected (H1, H2 and H3) and two pTRE-
transfected control (C1 and C2) MCF-7 clones were incubated with or without doxycycline. Whole cell protein extracts were 
prepared from untreated cells or cells treated with doxycycline for 48 hours. Extracts (25 ug protein/lane) were analyzed by 
Western blotting for the expression of survivin and phosphorylated HER-2).
Table 1: Cell cycle distribution of HER2 transfected MCF-7 cells
G1 S G2/M
MCF7-HER2 (- Dox) 66.34 14.97 18.68
MCF7-HER2 (+ Dox) 66.68 19.67 13.65
MCF7 Cells were cultured with (+ Dox) or without (- Dox) 
doxycycline for 48 hours, incubated with propidium iodide and 
analyzed for cell cycle distribution by flow cytometry.BMC Cancer 2008, 8:129 http://www.biomedcentral.com/1471-2407/8/129
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Activation of the ERK signal transduction pathways in 
response to HER-2 over-expression
Over-expression of HER-2 has been reported to activate
multiple signal transduction pathways including Ras-
MAPK, the PI3-K-Akt-NF-kappaB cascade and STAT 3
[24]. We determined the state of activation of these path-
ways in MCF7 cells after doxycycline-induced HER-2 over-
expression. Vector-transfected (pTRE) cells and MCF7-
HER2 cells were incubated with or without doxycycline
for 48 hours. Whole cell protein extracts were analyzed by
western blotting for expression of total ERK 1/2, STAT 3
and AKT 1 and their respective activated forms (phospho-
ERK 1/2, phospho-STAT3 and phospho-AKT-1; Figure 5).
There were no changes in the total levels of ERK 1/2, STAT
3 and AKT 1. In accordance with the previous reports, we
identified pronounced induction of phospho-ERK 1/2 in
doxycycline-treated MCF7-HER2 cells. However, there
were no changes in the levels of phospho-STAT 3 and
phospho-AKT (Ser473).
NF-kappaB is not activated in response to induction of 
HER-2 over-expression in MCF7 cells
Stimulation of a wide variety of cell-surface receptors
leads directly to NF-κB activation and a rapid change in
gene expression. To determine whether NF-kappaB is acti-
vated in response to induction of HER-2 in MCF7 cells we
transiently transfected control and doxycycline-treated
MCF7-HER2 cells with a plasmid containing firefly luci-
ferase sequence driven by five tandem consensus NF-kap-
paB elements. As demonstrated in Figure 6, there was no
significant increase in NF-kappaB-mediated luciferase
activity in cells with induced HER-2 overexpression as
compared to their uninduced counterparts.
Up-regulation of survivin in HER-2 induced MCF7 cells is 
via ERK activation and PI3K signalling
To investigate the regulation of survivin expression in
HER-2 induced MCF7 cells we used specific inhibitors of
the signal transduction pathways. HER-2 inducible MCF7
cells were incubated for 48 hours after addition of doxycy-
cline and/or signal pathway inhibitors and analyzed, by
western blotting for expression of survivin. We used PI3
kinase inhibitor – LY294002 (10 µM) and AKT IV inhibi-
tor (15 µM) that selectively inhibits the cellular phospho-
rylation/activation of AKT1/2/3 but does not inhibit
known upstream activators of AKT, i.e. PI3K or PDK. To
inhibit the MAPK pathway we used the Erk 1/2 inhibitor
U0126 (10 µM). As shown in figure 7A, a decrease in sur-
Activity of the survivin promoter is not enhanced by HER2  over-expression in MCF cells Figure 3
Activity of the survivin promoter is not enhanced by 
HER2 over-expression in MCF cells. MCF-HER2 cells 
were plated in duplicate wells at a concentration of 5 × 104 
cells per well in 24 well plates. Doxycycline (dox) or saline 
(control) was added 16 hours later and incubation continued 
for additional 24 hours, after which cells received fresh 
serum-containing medium with or without Dox. Cells were 
then co-transfected with a Survivin-Luc plasmid and pRL-TK, 
which contains the Renilla luciferase coding sequence under 
control of the TK promoter as a control for transfection. 48 
hours later cells were harvested and dual-luciferase assay was 
performed per manufacturer's instructions. Data are pre-
sented as a ratio of Firefly/Renilla luciferase ×100.
Bcl-2 is up-regulated in HER-2 expressing MCF7 cell line Figure 4
Bcl-2 is up-regulated in HER-2 expressing MCF7 cell 
line: pTRE-HER2 and pTRE-transfected MCF-7 clones were 
incubated with or without doxycycline for 48 hours. Whole 
cell protein extracts were collected and analyzed for expres-
sion of Bcl-2 by western blotting.BMC Cancer 2008, 8:129 http://www.biomedcentral.com/1471-2407/8/129
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vivin up-regulation was observed in the MCF7-HER2 cells
treated with ERK 1/2 inhibitor U0126 and PI3 kinase
inhibitor – LY294002, suggesting the involvement of
these pathways in the up-regulation of survivin. However
no significant change was observed by inhibition of acti-
vated AKT1/2/3 by AKT IV inhibitor. Inhibition of PI3
kinase and AKT was confirmed by decrease in phosphor-
ribosomal protein S6 (S235), the down stream target of
phospho-AKT [25] (figure 7B).
Discussion
Her-2/neu overexpression is associated with poor overall
survival and drug resistance in breast and ovarian cancer
patients. Although the molecular mechanisms by which
Her-2/neu induces drug resistance are not well estab-
lished, there is increasing evidence that this resistance is a
consequence of deregulation of apoptotic pathways in
cells. Chemotherapy, radiation, and immunotherapy all
rely heavily on apoptosis to kill breast cancer cells [26].
Therefore we investigated the pro- and anti apoptotic reg-
ulators and the signal transduction pathway(s) influenced
by tetracycline inducible HER-2 over-expression in MCF-7
breast cancer cell line. The advantage of tetracycline
inducible HER-2 expression is that the short-term effect of
increased HER-2 expression can be determined. We show
that acute over expression of HER-2 in MCF7 cells up-reg-
ulates the anti apoptotic protein Bcl-2. Bcl-2 is expressed
in 70% of breast cancers and it functions directly in apop-
tosis regulation and in oncogenesis. Oncogenes such as c-
Myc, which drive cells to enter the cell cycle, also engage
Bax/Bak-dependent apoptosis [27]. Antiapoptotic Bcl-2
family members can prevent such cell death and thereby
promote oncogenic transformation. Additionally high
expression level of anti-apoptotic Bcl-2 proteins confers a
clinically important chemoresistant phenotype on cancer
cells[28]. Likewise, reduced expression of pro-apoptotic
Analysis of total ERK 1/2, STAT 3, AKT 1 and their phospho- rylated forms in HER2-overexpressing and control cells Figure 5
Analysis of total ERK 1/2, STAT 3, AKT 1 and their 
phosphorylated forms in HER2-overexpressing and 
control cells. pTRE-HER2 and pTRE-transfected MCF-7 
clones were incubated with or without doxycycline for 48 
hours. Whole cell extracts were prepared and analyzed by 
Western blotting with the indicated antibodies. Experiments 
were repeated twice with independently collected extracts.
Activity of NF-kappaB in control and doxycycline-treated  MCF7-HER2 cells Figure 6
Activity of NF-kappaB in control and doxycycline-
treated MCF7-HER2 cells. MCF7-HER2 cells were plated 
in duplicate wells at a concentration of 5 × 104 cells per well 
in 24 well plates. Doxycycline (Dox) or saline (control) was 
added 16 hours later and incubation continued for additional 
48 hours, after which cells received fresh serum-containing 
medium with or without Dox. Cells were then co-trans-
fected with NF-kappaB-RE-Luc plasmid and pRL-TK, which 
contains Renilla luciferase sequence under control of TK 
promoter. 48 hours later cells were harvested and dual-luci-
ferase assay was performed per manufacturer's instructions. 
Data are presented as the ratio of Firefly/Renilla luciferase 
actvity × 100.BMC Cancer 2008, 8:129 http://www.biomedcentral.com/1471-2407/8/129
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Bax levels has been associated with poor response to
chemotherapy and shorter overall survival for patients
with breast cancers, whereas enhanced expression of Bax
protein correlate with a good response to chemotherapy
in vivo [29].
In the absence of new protein synthesis, survivin protein
level is expected to decrease steadily with a half-life of
approximately 30 minutes [23]. MCF7-HER2 cells, treated
with an inhibitor of protein synthesis cycloheximide
show a slower decrease in survivin protein level in HER-2
over-expressing MCF7 cells than in control cells (data not
shown), which suggests that up-regulation of survivin is
post translational. Expression of survivin in tumours cor-
relates with a poor clinical outcome in a variety of malig-
nancies including breast cancer by providing protection
against apoptotic stimuli [30]. It is noteworthy that we did
not observe a significant anti- apoptotic effect of survivin
up regulation after treatment of HER2 over-expressing
MCF7 cells with taxol, adriamycin and herceptin (data not
shown). This suggests that unlike stable over expression of
HER2, an inducible short term HER2 expression and
upregulation of survivin is not enough to exert an anti-
apoptotic effect.
Growth and survival signals elicited by activated HER-2
are largely mediated via PI3K-Akt and Ras-MAPK signal-
ing pathways. Using specific PI3K, ERK and AKT inhibi-
tors, we show that PI3K and ERK signalling are
responsible for up-regulation of survivin in MCF7-Her2
cells. Inhibition of pAKT did not down-regulate survivin
in these cells. The exact role of Akt in this process remains
to be determined. Down-regulation of survivin may occur
independent of p-Akt expression. PI3K-dependent, but
Akt-independent, mechanisms by which HER-2 might
regulate survivin include effects on serum- and glucocorti-
coid-induced kinases (SGK), which are serine/threonine
kinases that are highly homologous to Akt and, like Akt,
are regulated by PI3K. Although the effects of SGK on sur-
vivin have not been studied, SGK regulates cell survival
[31] and may therefore be a candidate for regulating sur-
vivin protein expression. In addition, PI3K affects cell sur-
vival through a protein kinase C-dependent pathway that
is mediated by phospholipase Cγ activity [32]. Thus, it is
possible that HER-2 regulates survivin in part through
PI3K-dependent effects on SGK and/or phospholipase Cγ.
Conclusion
After a short term (48 hours) induction of HER2 in MCF7
breast cancer cells anti-apoptotic proteins survivin and
Bcl-2 are up-regulated. PI3K and ERK but not the NF-kap-
paB, STAT3 and AKT signalling are involved in up-regula-
tion of survivin. Regulation of survivin in HER-2-positive
MCF7 cells is not at transcriptional level. Understanding
the regulation of HER-2 signalling pathways will help to
identify new targets/strategies for the treatment of patients
Signaling pathways involved in survivin regulation in HER2 over expressing MCF7cells Figure 7
Signaling pathways involved in survivin regulation in HER2 over expressing MCF7cells. A- HER2 induced MCF7 
cells were incubated for 48 hours with specific inhibitors of PI3K (10 µM LY294002) AKT1/2/3 (15 µM AKT IV Inhibitor) and 
ERK1/2 (10 µM U0126) or without inhibitor (control) and analyzed by western blotting for expression of survivin. B- To con-
firm the inhibition of AKT and PI3K, HER2 induced MCF7 cells were incubated for 48 hours with specific inhibitors of PI3K (10 
µM LY294002) AKT1/2/3 (15 µM AKT IV Inhibitor). ERK1/2 (10 µM U0126) and without inhibitor MCF-7 cells were used as 
controls, and analyzed by western blotting for expression of phospho-ribosomal protein S6 (S235).BMC Cancer 2008, 8:129 http://www.biomedcentral.com/1471-2407/8/129
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with tumours that are dependent on HER-2 induced sig-
nalling pathways for their survival.
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